XERS

$5.61

Pre-MarketAs of Mar 17, 8:00 PM UTC

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$5.61
Potential Downside
100%
Whystock Fair Value$0.00
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$967.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.48

Recent News

Simply Wall St.
Mar 3, 2026

Xeris Biopharma Balances New Profitability With Recorlev Patent Battles

Xeris Biopharma Holdings (NasdaqGS:XERS) has reported financial self-sustainability and its first full year of net income. Recent results are supported by strong revenue contribution from its core product portfolio. The company is pursuing multiple patent infringement lawsuits to protect Recorlev from generic challengers. At a share price of $6.02, Xeris Biopharma sits after a 63.1% return over the past year and a 3-year gain of 315.2%. The stock has seen a 7-day return of an 8.5% decline,...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 2, 2026

Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...

Xeris Biopharma Holdings Inc (XERS) reports robust financial performance with significant revenue growth and strategic plans for 2026, despite ongoing legal challenges.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Mar 2, 2026

Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary

Moby summary of Xeris Biopharma Holdings, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Motley Fool
Mar 2, 2026

Xeris Biopharma (XERS) Q4 2025 Earnings Transcript

Now as we enter 2026, we do so with clear momentum positioned to drive rapid revenue growth, execute on our advanced pipeline and thoughtfully prepare for even greater opportunities ahead. The performance you delivered in 2025 and the strength of our outlook for 2026 is a direct result of your extraordinary commitment, focus and disciplined execution across every part of our enterprise. Fourth quarter total revenue grew 43% year-over-year to nearly $86 million.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 2, 2026

Xeris Biopharma Q4 Earnings Call Highlights

Xeris Biopharma (NASDAQ:XERS) reported sharp top-line growth in the fourth quarter and full year 2025, highlighted by what management described as a “defining milestone” for the company: financial self-sustainability. On its fourth quarter earnings call, executives also outlined a 2026 outlook calli

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.